IDG 16177
Alternative Names: IDG-16177Latest Information Update: 02 Oct 2021
At a glance
- Originator Ildong Pharmaceutical
- Developer Evotec SE; Ildong Pharmaceutical
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Beta-arrestin stimulants; FFAR1 protein stimulants; Gastrointestinal hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 01 Jul 2021 Phase-I clinical trials in Type 2 diabetes mellitus (Combination therapy) in Germany (PO)
- 01 Jul 2021 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Germany (PO)
- 28 Jun 2021 The Federal Institute for Drugs and Medical Devices (BfArM) of German regulatory authority approves phase I trial for IDG 16177 in Type 2 diabetes mellitus in Germany